BRPI0515668A - tratamento de osteoporose induzida por privação de androgênio - Google Patents

tratamento de osteoporose induzida por privação de androgênio

Info

Publication number
BRPI0515668A
BRPI0515668A BRPI0515668-8A BRPI0515668A BRPI0515668A BR PI0515668 A BRPI0515668 A BR PI0515668A BR PI0515668 A BRPI0515668 A BR PI0515668A BR PI0515668 A BRPI0515668 A BR PI0515668A
Authority
BR
Brazil
Prior art keywords
induced osteoporosis
androgen deprivation
toremifene
isomer
incidence
Prior art date
Application number
BRPI0515668-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Mitchell STEINER
Karen Veverka
Raghow A Sharan
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Inc filed Critical Gtx Inc
Publication of BRPI0515668A publication Critical patent/BRPI0515668A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0515668-8A 2004-09-20 2005-09-19 tratamento de osteoporose induzida por privação de androgênio BRPI0515668A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/944,465 US20050080143A1 (en) 2001-11-29 2004-09-20 Treatment of androgen-deprivation induced osteoporosis
PCT/US2005/032998 WO2006033979A1 (en) 2004-09-20 2005-09-19 Treatment of androgen - deprivation induced osteoporosis

Publications (1)

Publication Number Publication Date
BRPI0515668A true BRPI0515668A (pt) 2008-07-29

Family

ID=36090335

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515668-8A BRPI0515668A (pt) 2004-09-20 2005-09-19 tratamento de osteoporose induzida por privação de androgênio

Country Status (12)

Country Link
US (1) US20050080143A1 (enExample)
EP (2) EP1796643A4 (enExample)
JP (2) JP2008513469A (enExample)
KR (1) KR20070059167A (enExample)
CN (2) CN101961327A (enExample)
AU (1) AU2005287113B2 (enExample)
BR (1) BRPI0515668A (enExample)
CA (1) CA2581159A1 (enExample)
EA (1) EA014309B1 (enExample)
IL (1) IL182091A0 (enExample)
MX (1) MX2007003272A (enExample)
WO (1) WO2006033979A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
CN116869944A (zh) * 2023-08-15 2023-10-13 重庆士立德医药科技有限公司 一种托瑞米芬组合物及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
GB8508404D0 (en) * 1985-03-30 1985-05-09 Baylor College Medicine Therapeutic compositions
US4897254A (en) * 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
FR2578113B1 (fr) * 1985-02-25 1988-04-15 Merlin Gerin Declencheur statique numerique a fonctions optionnelles pour un disjoncteur electrique
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
ES2189784T3 (es) * 1989-07-07 2003-07-16 Endorech Inc Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
US5153622A (en) * 1989-08-03 1992-10-06 Asahi Kogaku Kogyo Kabushiki Kaisha Pressure alarm for water-sealed camera
JPH06287885A (ja) * 1991-04-15 1994-10-11 Yamauchi Corp 脱水プレス用エンドレスベルト
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
TW303299B (enExample) * 1993-07-22 1997-04-21 Lilly Co Eli
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
CA2248769A1 (en) * 1996-03-18 1997-09-25 The Trustees Of The University Of Pennsylvania Bioactive material substrate for enhanced cellular attachment and function
GB9712086D0 (en) * 1997-06-10 1997-08-13 Bp Chem Int Ltd Process for preparing polyketones
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
EP2277514A1 (en) * 1998-05-07 2011-01-26 The University Of Tennessee Research Corporation A method for chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6410043B1 (en) * 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
EP1102755B1 (en) * 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
US6165504A (en) * 1998-09-23 2000-12-26 Barr Laboratories, Inc. Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
US6258802B1 (en) * 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
CN1400904A (zh) * 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
EP1289519B1 (en) * 2000-05-26 2019-02-13 Harry Fisch Methods of treating androgen deficiency in men using clomiphene
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
US20030158160A1 (en) * 2000-07-05 2003-08-21 Barrington Furr Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
PT1210951E (pt) * 2000-11-30 2005-04-29 Pfizer Prod Inc Composicao que contem agonistas/antagonistas de estrogeneo e testosterona para tartamento de um declinio do nivel da hormona testosterona
US6413633B1 (en) * 2001-04-18 2002-07-02 Francis Patrick McCullough Activated biregional fiber(s)
WO2002091993A2 (en) * 2001-05-10 2002-11-21 Merck & Co., Inc. Estrogen receptor modulators
DE02726901T1 (de) * 2001-05-17 2004-07-15 Immunex Corp., Seattle Therapeutische verwendung von rang-antagonisten
DK1666033T3 (da) * 2001-11-29 2009-04-06 Gtx Inc Forebyggelse og behandling af ved androgenmangel fremkaldt osteoporose
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20040152733A1 (en) * 2002-03-15 2004-08-05 Wallace Owen Brendan Duloxetine for treatment of hot flashes
KR20050049476A (ko) * 2002-08-14 2005-05-25 파마시아 앤드 업존 캄파니 엘엘씨 홍조를 치료하기 위한 레복세틴의 용도
JP4115913B2 (ja) * 2002-08-23 2008-07-09 エーエスエムエル ネザーランズ ビー．ブイ． リソグラフィ投影装置及び前記装置で使用する微粒子バリヤ
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20070042040A1 (en) * 2003-04-30 2007-02-22 Herve Porchet Methods and compositions using gonadotropin hormone releasing hormone
US7048210B2 (en) * 2003-05-21 2006-05-23 Frank Clark Showerhead with grooved water release ducts
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof

Also Published As

Publication number Publication date
MX2007003272A (es) 2007-06-05
EP1935415A2 (en) 2008-06-25
EP1796643A4 (en) 2009-09-09
EA014309B1 (ru) 2010-10-29
EP1796643A1 (en) 2007-06-20
WO2006033979A1 (en) 2006-03-30
CN101056621B (zh) 2010-11-10
CN101961327A (zh) 2011-02-02
JP2009029823A (ja) 2009-02-12
US20050080143A1 (en) 2005-04-14
IL182091A0 (en) 2011-08-01
CN101056621A (zh) 2007-10-17
AU2005287113B2 (en) 2011-06-16
JP2008513469A (ja) 2008-05-01
CA2581159A1 (en) 2006-03-30
EA200700690A1 (ru) 2007-10-26
EP1935415A3 (en) 2009-09-16
KR20070059167A (ko) 2007-06-11
AU2005287113A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2003047504A3 (en) Prevention and treatment of androgen-deprivation induced osteoporosis
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
CY1108201T1 (el) Συσκευες διαδερματικης απελευθερωσης οπιοειδους που ειναι ανθεκτικες στην παραβιαση
PT1286671E (pt) Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
AU2003268144A8 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
WO2004064734A3 (en) Combination therapies for the treatment of cancer
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
MXPA06001110A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
BRPI0406674A (pt) Composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de um aditivo farmaceuticamente aceitável, método para o tratamento ou prevenção de dor aguda ou crÈnica, dispositivo para pulverização, e, processo para preparar uma composição
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
BRPI0515668A (pt) tratamento de osteoporose induzida por privação de androgênio
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0214135A (pt) Produto farmacêutico, dose farmacêutica, usos de um anti-estrogênio e de um inibidor da aromatase e 4'-ciano-alfa', alfa, alfa'-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2- metilpropiono-m-toluidida ou um sal ou solvato farmaceuticamente aceitáveis destes, e, método para tratar de câncer da próstata e/ou reduzir o risco de câncer da próstata em um paciente
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
Arora et al. Narrowband ultraviolet B and beyond: Evolving role of phototherapy in vitiligo
Chen et al. Stroke treatment in rats with tail temperature increase by 40-min moxibustion
Cham Topical Curaderm BEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes
BRPI0404050A (pt) Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
WO2005046594A3 (en) Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
Weinrauch et al. Current therapy of cutaneous leishmaniasis.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.